αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo

Ping Zhong,1,2 Xiaolei Gu,1,2 Ru Cheng,1,2 Chao Deng,1,2 Fenghua Meng,1,2 Zhiyuan Zhong1,2 1Biomedical Polymers Laboratory, 2Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, Ch...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhong P, Gu X, Cheng R, Deng C, Meng F, Zhong Z
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/3889f45e6eee46d1b39e8760175e1826
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3889f45e6eee46d1b39e8760175e1826
record_format dspace
spelling oai:doaj.org-article:3889f45e6eee46d1b39e8760175e18262021-12-02T01:14:33Zαvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo1178-2013https://doaj.org/article/3889f45e6eee46d1b39e8760175e18262017-10-01T00:00:00Zhttps://www.dovepress.com/alphavbeta3-integrin-targeted-micellar-mertansine-prodrug-effectively--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Ping Zhong,1,2 Xiaolei Gu,1,2 Ru Cheng,1,2 Chao Deng,1,2 Fenghua Meng,1,2 Zhiyuan Zhong1,2 1Biomedical Polymers Laboratory, 2Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, China Abstract: Antibody-mertansine (DM1) conjugates (AMCs) are among the very few active targeting therapeutics that are approved or clinically investigated for treating various cancers including metastatic breast cancer. However, none of the AMCs are effective for the treatment of triple-negative breast cancers (TNBCs). Here, we show that cRGD-decorated, redox-activatable micellar mertansine prodrug (cRGD-MMP) can effectively target and deliver DM1 to αvβ3 integrin overexpressing MDA-MB-231 TNBC xenografts in nude mice, resulting in potent tumor growth inhibition. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays showed that cRGD-MMP had obvious targetability to MDA-MB-231 cells with a low half-maximal inhibitory concentration (IC50) of 0.18 µM, which was close to that of free DM1 and 2.2-fold lower than that of micellar mertansine prodrug (MMP; nontargeting control). The confocal microscopy studies demonstrated that cRGD-MMP mediated a clearly more efficient cellular uptake and intracellular release of doxorubicin (used as a fluorescent anticancer drug model) in MDA-MB-231 cells. Notably, cRGD-MMP loaded with 1,1'-dioctadecyltetramethyl indotricarbocyanine iodide (DiR; a hydrophobic near-infrared dye) was shown to quickly accumulate in the MDA-MB-231 tumor with strong DiR fluorescence from 2 to 24 h post injection. MMP loaded with DiR could also accumulate in the tumor, although significantly less than cRGD-MMP. The biodistribution studies revealed a high DM1 accumulation of 8.1%ID/g in the tumor for cRGD-MMP at 12 h post injection. The therapeutic results demonstrated that cRGD-MMP effectively suppressed MDA-MB-231 tumor growth at 1.6 mg DM1 equiv./kg without causing noticeable side effects, as shown by little body weight loss and histological analysis. This MMP has appeared as a promising platform for potent treatment of TNBCs. Keywords: breast cancer, reduction-sensitive, drug conjugates, micelles, cRGDZhong PGu XCheng RDeng CMeng FZhong ZDove Medical PressarticleBreast cancerreduction-sensitivedrug conjugatesmicellescRGDMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 7913-7921 (2017)
institution DOAJ
collection DOAJ
language EN
topic Breast cancer
reduction-sensitive
drug conjugates
micelles
cRGD
Medicine (General)
R5-920
spellingShingle Breast cancer
reduction-sensitive
drug conjugates
micelles
cRGD
Medicine (General)
R5-920
Zhong P
Gu X
Cheng R
Deng C
Meng F
Zhong Z
αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
description Ping Zhong,1,2 Xiaolei Gu,1,2 Ru Cheng,1,2 Chao Deng,1,2 Fenghua Meng,1,2 Zhiyuan Zhong1,2 1Biomedical Polymers Laboratory, 2Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, China Abstract: Antibody-mertansine (DM1) conjugates (AMCs) are among the very few active targeting therapeutics that are approved or clinically investigated for treating various cancers including metastatic breast cancer. However, none of the AMCs are effective for the treatment of triple-negative breast cancers (TNBCs). Here, we show that cRGD-decorated, redox-activatable micellar mertansine prodrug (cRGD-MMP) can effectively target and deliver DM1 to αvβ3 integrin overexpressing MDA-MB-231 TNBC xenografts in nude mice, resulting in potent tumor growth inhibition. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays showed that cRGD-MMP had obvious targetability to MDA-MB-231 cells with a low half-maximal inhibitory concentration (IC50) of 0.18 µM, which was close to that of free DM1 and 2.2-fold lower than that of micellar mertansine prodrug (MMP; nontargeting control). The confocal microscopy studies demonstrated that cRGD-MMP mediated a clearly more efficient cellular uptake and intracellular release of doxorubicin (used as a fluorescent anticancer drug model) in MDA-MB-231 cells. Notably, cRGD-MMP loaded with 1,1'-dioctadecyltetramethyl indotricarbocyanine iodide (DiR; a hydrophobic near-infrared dye) was shown to quickly accumulate in the MDA-MB-231 tumor with strong DiR fluorescence from 2 to 24 h post injection. MMP loaded with DiR could also accumulate in the tumor, although significantly less than cRGD-MMP. The biodistribution studies revealed a high DM1 accumulation of 8.1%ID/g in the tumor for cRGD-MMP at 12 h post injection. The therapeutic results demonstrated that cRGD-MMP effectively suppressed MDA-MB-231 tumor growth at 1.6 mg DM1 equiv./kg without causing noticeable side effects, as shown by little body weight loss and histological analysis. This MMP has appeared as a promising platform for potent treatment of TNBCs. Keywords: breast cancer, reduction-sensitive, drug conjugates, micelles, cRGD
format article
author Zhong P
Gu X
Cheng R
Deng C
Meng F
Zhong Z
author_facet Zhong P
Gu X
Cheng R
Deng C
Meng F
Zhong Z
author_sort Zhong P
title αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
title_short αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
title_full αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
title_fullStr αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
title_full_unstemmed αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
title_sort αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/3889f45e6eee46d1b39e8760175e1826
work_keys_str_mv AT zhongp alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
AT gux alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
AT chengr alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
AT dengc alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
AT mengf alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
AT zhongz alphavbeta3integrintargetedmicellarmertansineprodrugeffectivelyinhibitstriplenegativebreastcancerinvivo
_version_ 1718403191788273664